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Background and aims : Cardiac autonomic neuropathy (CAN) is a frequent complication of 
diabetes mellitus. The present work aimed at analysing the influence of blood glucose control 
on the progression of indices of CAN in patients with type 1 diabetes mellitus.   
 
Materials and methods : 48 (28 women and 20 men) patients with type 1 diabetes (mean ± 
SD : age : 41 ± 12 years; diabetes duration : 19 ± 10 years with  a range from 3 to 38 years) 
were studied twice at a time interval of 43 ± 17 months (range : 16-91 months). Patients 
taking drugs interfering with cardiovascular regulation were excluded. CAN was assessed by 
calculating the baroreflex gain during a squatting test (1 min standing – 1 min squatting – 1 
min standing) while continuous monitoring of heart rate and arterial blood pressure with a 
FinapresR device. The baroreflex gain was calculated by plotting R-R cardiac intervals 
according to mean arterial blood pressure values during the transition active phase from 
squatting to standing. Overall blood glucose control was estimated by the mean value of 
several HbA1c measurements between the two tests, and subjects were separated into two 
subgroups : HbA1c levels < 8 % in 21 patients (7.42 ± 0.60 %) versus > 8 % in 27 patients 
(9.44 ± 1.04 %). 
 
Results : The baroreflex gain tended to be negatively related to the duration of diabetes at the 
initial evaluation (r = - 0.174; n = 48; p < 0.10). This index of CAN decreased from 4.00 ± 
3.41 to 2.53 ± 1.46msec/mm Hg (p = 0.008) during the 43-month period separating the two 
orthostatic tests. The reduction in baroreflex gain was significant in patients with bad glucose 
control  (from 3.89 to 2.13 msec/mm Hg, p  = 0.02), but not in patients with acceptable 
control (from  4.16 to 3.05 msec/mm Hg, NS). While no significant differences were observed 
between the two groups at the initial evaluation, baroreflex gain became significantly lower in 
the poorly controlled group than in the better controlled group at the second evaluation (p < 
0.05). A significant negative correlation was found between changes in baroreflex gain from 
test 1 to test 2 and mean HbA1c levels (r = - 0.304; n = 48; p < 0.01), and between baroreflex 
gain at the second test and averaged HbA1c during the period between the two tests (r =  - 
0.409; n = 48; p < 0.001).  Interestingly, pulse pressure significantly increased from test 1 to 
test 2 in patients with poor metabolic control (from 47.3 to 57.6 mm Hg; p < 0.001), but not in 
patients with better metabolic control (from 50.4 to 56.6 mm Hg; NS).  
Conclusion : In patients with long-standing (almost 20 years) type 1 diabetes, a period of 3-4 
years with poor glucose control is sufficient to significantly decrease baroreflex gain, an index 
of cardiac autonomic neuropathy, and to increase pulse pressure, an index of arterial stiffness, 
two independent risk markers in patients with diabetes mellitus. These observations support 
the search of better metabolic control in patients with  type 1 diabetes, with a minimum 
objective of HbA1c levels below  7 %.   
